Study of Neoadjuvant Chemotherapy of Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions
Breast Cancer
Interventions
DRUG

Neoadjuvant chemotherapy

Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab

DRUG

Chemotherapy

Neoadjuvant chemotherapy

DRUG

Neoadjuvant chemotherapy

Experimental chemotherapy regimen

Trial Locations (1)

00927

Auxilio Mutuo Cancer Center, San Juan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Auxilio Mutuo Cancer Center

OTHER